INS and myeloid sarcoma: In turn, the impaired ability of insulin to inhibit glucose production in MS patients leads to the occurrence of hyperglycemia and increased insulin secretion, which may lead to the development of type II diabetes, which may predispose to the progression of NAFLD [9].